Myriad Genetics (NASDAQ:MYGN) reported Q3 earnings this Morning, coming in at $0.31 per share, beating Wall Street’s estimates of $0.27 per Share. Revenue for the quarter came in at $193.50 million beating analyst estimates of $188.22 million Recent Insider Trading for Myriad Genetics (NASDAQ:MYGN)
- On 1/22/2018 Richard M Marsh, VP, sold 37,654 with an average share price of $40.25 per share and the total transaction amounting to $1,515,573.50.
- On 1/18/2018 Gary A King, VP, sold 3,120 with an average share price of $38.12 per share and the total transaction amounting to $118,934.40.
- On 1/12/2018 Richard M Marsh, VP, sold 13,759 with an average share price of $36.25 per share and the total transaction amounting to $498,763.75.
- On 12/14/2017 Walter Phd Gilbert, Director, sold 7,500 with an average share price of $33.19 per share and the total transaction amounting to $248,925.00.
- On 12/11/2017 Heinrich Dreismann, Director, sold 6,000 with an average share price of $33.50 per share and the total transaction amounting to $201,000.00.
- On 11/13/2017 Alexander Ford, Insider, sold 3,031 with an average share price of $31.64 per share and the total transaction amounting to $95,900.84.
Dividend History for Myriad Genetics (NASDAQ:MYGN)
Recent Trading for Myriad Genetics (NASDAQ:MYGN) Shares of Myriad Genetics closed the previous trading session at 30.36 up +1.38 4.76% with 29.3799991607666 shares trading hands.